When you ask the intern for the patient’s oncologic history on rounds:

The dramatic difference between leg room one gets in economy compared to economy plus seems like an ominous symptom of declining solidarity in US society. But also: I’m never flying regular economy again.

If you last checked in on AI image makers a month ago & thought “that is a fun toy, but is far from useful…” Well, in just the last week or so two of the major AI systems updated. You can now generate a solid image in one try. For example, “otter on a plane using wifi” 1st try:

Our latest study in JAMA Surgery revealed that spending for cancer surgery decreased significantly among Medicare beneficiaries. Read the full text: jamanetwork.com/journals/jamas… Alex Melamed @NancyKeatingMD @anaeze_offodile

Nice study from Vrede et al: The molecular subtype may not be prognostically important for low-grade endometrioid endometrial cancer Relevance of Molecular Profiling in Patients With Low-Grade Endometrial Cancer ja.ma/3jNizKm via JAMA Network Open part of JAMA Network

A new paper by Jason Silberman Jason Silberman, MD: who is on the market for the gyn onc fellowship spot! tinyurl.com/2pzjm748 cytotoxic NACT has increased for stage III&IV low-grade serous ovarian cancer in last 15y w/o evidence that this approach is effective in this cancer type

A new paper by super intern Katy Abel looks at the use and efficacy of primary site surgery in metastatic cancer. There is a lot of heterogeneity across cancer sites, raising essential questions about how, and if, we know when surgery is helpful onlinelibrary.wiley.com/doi/full/10.10…

Thanks IJGC and Pedro T Ramirez for this great honor.

Since 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery has become the most prevalent approach of upfront treatment for patients with advanced epithelial ovarian cancer in the US. ja.ma/4dNCjEa

NACT and interval cytoreductive surgery edges out primary cytoreductive surgery as the most frequent treatment for advanced-stage ovarian cancer in the US. 11 years after Vergote et al. It really does take a decade.

Cool picture of a adenosarcoma assocaited uterine inversion which we treated laparoscopically. Nice work by Baran Vardar and Alex Bercow, MD getting these pictures into the literature. pubs.rsna.org/doi/10.1148/ry…

What an honor for us to host Giovanni Scambia and Anna Fagotti at MGH OBGYN.

#cancer during #pregnancy is associated with severe maternal and neonatal morbidity. Proud of the entire team for this important manuscript! authors.elsevier.com/c/1k7m2gm3zE9I J. Alejandro Rauh-Hain, MD, MPH Alex Melamed @markaclapp Abigail S. Zamorano, MD MPHS David Viveros-Carreño Núria Agustí Garcia MD Anderson Cancer Center AJOG

LANCE trial lead-in pilot shows the feasibility of a phase III study to evaluate the efficacy of MIS for interval cytoreduction in ovarian cancer. J. Alejandro Rauh-Hain, MD, MPH Anna Fagotti René Pareja Pedro T Ramirez Abdulrahman K. Sinno

Our 15-year cohort study explores trends in surgical de-escalation in gynecologic oncology. These findings are transforming patient care but raise important questions about the preparation of fellows in surgical training. Alex Melamed David Viveros-Carreño J. Alejandro Rauh-Hain, MD, MPH Roni Nitecki Wilke

youtu.be/LPEYsazrKIw?si…

Our JAMA Oncology study is now featured in the IJGC podcast! Thank you for highlighting our work. Grateful to work with such an amazing team! David Viveros-Carreño Alex Melamed Roni Nitecki Wilke René Pareja J. Alejandro Rauh-Hain, MD, MPH

Our latest lead by Dr. Katy Abel. More evidence that underutilization of NACT is associated with worse post-operative outcomes, without any hint of long-term benefit, even in high-volume centers.